T-VEC Immunotherapy Shows Promising Early Activity in Melanoma

Source: Cancer Network, June 2018

Twelve weeks of neoadjuvant exposure to talimogene laherparepvec (T-VEC) was associated with few high-grade toxicities and a promising pathological complete tumor-response (pCR) rate, according to research (abstract 9508) presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 1–5 in Chicago.

The interim analysis of neoadjuvant T-VEC demonstrates impressive clinical response in resectable disease,” commented Joshua M.V. Mammen, MD, PhD, of the University of Kansas in Kansas City in a poster-discussion panel. Mammen was not involved in the study.

However, 11 patients (14.5%) in the T-VEC study arm experienced disease progression before surgery could be performed. That might reflect the “high risk of developing metastases inherent within this study population,” and some of those patients were unlikely to have benefitted from surgery, the study authors argued.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories